Kosiborod, M. ., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K. ., Holl, R. W., … Fenici, P. . (2017). Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotranspo. Circulation. http://doi.org/10.1161/circulationaha.117.029190
P. Fenici
First name
P.
Last name
Fenici
Wilding, J. ., Godec, T. ., Khunti, K. ., Pocock, S. ., Fox, R. ., Smeeth, L. ., … Medina, J. . (2017). Changes in HbA1c and weight after initiation of second-line therapy in patients with type 2 diabetes in clinical practice. Diabetologia.
Cavender, M. A., Norhammar, A. ., Birkeland, K. I., Jorgensen, M. E., Wilding, J. P., Khunti, K. ., … Kosiborod, M. . (2018). SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. J Am Coll Cardiol. http://doi.org/10.1016/j.jacc.2018.01.085
Wilding, J. ., Godec, T. ., Khunti, K. ., Pocock, S. ., Fox, R. ., Smeeth, L. ., … Medina, J. . (2018). Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Med. http://doi.org/10.1186/s12916-018-1085-8
J, P. H. W., Rigney, U. ., Blak, B. T., Nolan, S. T., Fenici, P. ., & Medina, J. . (2019). Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. http://doi.org/10.1016/j.diabres.2019.107791
Heerspink, H. J. L., Karasik, A. ., Thuresson, M. ., Melzer-Cohen, C. ., Chodick, G. ., Khunti, K. ., … Kosiborod, M. . (2020). Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. http://doi.org/10.1016/s2213-8587(19)30384-5